Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.

PubMed  PubMed Central  Google Scholar 

Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS ONE. 2018;13(4):e0195687.

PubMed  PubMed Central  Google Scholar 

Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metrics. 2010;8(1):24.

Google Scholar 

Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, Yu Y, Kou C, Xu X, Lu J. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–24.

PubMed  Google Scholar 

Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.

Google Scholar 

Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.

PubMed  Google Scholar 

Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357.

PubMed  PubMed Central  Google Scholar 

Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203.

PubMed  PubMed Central  Google Scholar 

Mesa-Herrera F, Taoro-González L, Valdés-Baizabal C, Diaz M, Marín R. Lipid and lipid raft alteration in aging and neurodegenerative diseases: a window for the development of new biomarkers. Int J Mol Sci. 2019;20(15):3810.

PubMed Central  CAS  Google Scholar 

Rao W, Du X, Zhang Y, Yu Q, Hui L, Yu Y, Kou C, Yin G, Zhu X, Man L. Association between forkhead-box P2 gene polymorphism and clinical symptoms in chronic schizophrenia in a Chinese population. J Neural Transm. 2017;124(7):891–7.

PubMed  CAS  Google Scholar 

Yogaratnam J, Biswas N, Vadivel R, Jacob R. Metabolic complications of schizophrenia and antipsychotic medications-an updated review. East Asian Arch Psychiatry. 2013;23(1):21.

PubMed  CAS  Google Scholar 

An H-M, Tan Y-L, Tan S-P, Shi J, Wang Z-R, Yang F-D, Huang X-F, Soars JC, Kosten TR, Zhang X-Y. Smoking and serum lipid profiles in schizophrenia. Neurosci Bull. 2016;32(4):383–8.

PubMed  PubMed Central  Google Scholar 

Forero DA, López-León S, González-Giraldo Y, Dries DR, Pereira-Morales AJ, Jiménez KM, Franco-Restrepo JE. APOE gene and neuropsychiatric disorders and endophenotypes: a comprehensive review. Am J Med Genet B Neuropsychiatr Genet. 2018;177(2):126–42.

PubMed  CAS  Google Scholar 

Villeneuve S, Brisson D, Marchant NL, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154.

PubMed  PubMed Central  Google Scholar 

Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6(4):345–51.

PubMed  CAS  Google Scholar 

Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspect Med. 2012;2(3):a006312.

Google Scholar 

Eisenberg DT, Kuzawa CW, Hayes MG. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol. 2010;143(1):100–11.

PubMed  Google Scholar 

dbSNP Short Genetic Variations: reference SNP (rs) report. 2021. https://wwwncbinlmnihgov/snp/rs429358?vertical_tab=true#frequency_tab. Released April 9, 2021. ; Accessed 4 Jul 2021.

Babenko VN, Afonnikov DA, Ignatieva EV, Klimov AV, Gusev FE, Rogaev EI. Haplotype analysis of APOE intragenic SNPs. BMC Neurosci. 2018;19(Suppl 1):16–16.

PubMed  PubMed Central  Google Scholar 

González-Castro TB, Tovilla-Zárate CA, Hernández-Díaz Y, Fresán A, Juárez-Rojop IE, Ble-Castillo JL, López-Narváez L, Genis A, Hernández-Alvarado MM. No association between ApoE and schizophrenia: evidence of systematic review and updated meta-analysis. Schizophr Res. 2015;169(1):355–68.

PubMed  Google Scholar 

Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res. 2010;7(2):158–64.

PubMed  CAS  Google Scholar 

Panza F, Frisardi V, Seripa D, D’Onofrio G, Santamato A, Masullo C, Logroscino G, Solfrizzi V, Pilotto A. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer’s disease. Ageing Res Rev. 2012;11(1):87–103.

PubMed  CAS  Google Scholar 

Panza F, Seripa D, D’Onofrio G, Frisardi V, Solfrizzi V, Mecocci P, Pilotto A. Neuropsychiatric symptoms, endophenotypes, and syndromes in late-onset Alzheimer’s disease: focus on APOE gene. Int J Alzheimer’s Dis. 2011;2011:1–14.

Google Scholar 

Egert S, Rimbach G, Huebbe P. ApoE genotype: from geographic distribution to function and responsiveness to dietary factors. Proc Nutr Soc. 2012;71(3):410–24.

PubMed  CAS  Google Scholar 

Radwan ZH, Wang X, Waqar F, Pirim D, Niemsiri V, Hokanson JE, Hamman RF, Bunker CH, Barmada MM, Demirci FY. Comprehensive evaluation of the association of APOE genetic variation with plasma lipoprotein traits in US whites and African blacks. PLoS ONE. 2014;9(12):e114618.

PubMed  PubMed Central  Google Scholar 

Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham Study over 35 years. J Am Heart Assoc. 2019;8(11):e011433.

PubMed  PubMed Central  CAS  Google Scholar 

Orozco-Beltran D, Gil-Guillen VF, Redon J, Martin-Moreno JM, Pallares-Carratala V, Navarro-Perez J, Valls-Roca F, Sanchis-Domenech C, Fernandez-Gimenez A, Perez-Navarro A. Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: the ESCARVAL-RISK study. PLoS ONE. 2017;12(10):e0186196.

PubMed  PubMed Central  Google Scholar 

Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47(11):1549–56.

PubMed  Google Scholar 

Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H, Diao F, Wang J, Zheng L, Zhao J, et al. The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. Schizophr Res. 2013;150(1):157–62.

PubMed  Google Scholar 

Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, Darie CC. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med. 2012;16(6):1184–95.

PubMed  PubMed Central  CAS  Google Scholar 

Boiko AS, Mednova IA, Kornetova EG, Semke AV, Bokhan NA, Loonen AJ, Ivanova SA. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon. 2019;5(7):e02033.

PubMed  PubMed Central  Google Scholar 

Demmer LA, Levin MS, Elovson J, Reuben MA, Lusis AJ, Gordon JI. Tissue-specific expression and developmental regulation of the rat apolipoprotein B gene. Proc Natl Acad Sci. 1986;83(21):8102–6.

PubMed  PubMed Central  CAS  Google Scholar 

Mayo Clinic Laboratories: APOAB—clinical: apolipoprotein A1 and B, Serum. 2021. https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/607593. Accessed 4 Jul 2021.

Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X, Yusuf S. Lipoprotein (a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472–82.

PubMed  Google Scholar 

Martins-De-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T, Falkai P, Turck CW. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry. 2010;11(5):719–28.

PubMed  Google Scholar 

Wen F, Tan J. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects. Acta Pharmacol Sin. 2003;24(10):1001–5.

PubMed  CAS  Google Scholar 

Ozornin A, Govorin N. Blood lipid spectrum changes in first-episode schizophrenia patients treated with risperidone and haloperidol. Eur Psychiatry. 2013;28(S1):1.

Google Scholar 

Mabrouk H, Mechria H, Mechri A, Azizi I, Neffati F, Douki W, Gaha L, Najjar MF. Paraoxonase 1 activity and lipid profile in schizophrenic patients. Asian J Psychiatr. 2014;9:36–40.

PubMed  Google Scholar 

Walss-Bass C, Lokesh GL, Dyukova E, Gorenstein DG, Roberts DL, Velligan D, Volk DE. X-Aptamer technology identifies C4A and ApoB in blood as potential markers for schizophrenia. Mol Neuropsychiatr. 2019;5(1):52–9.

CAS  Google Scholar 

Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone H, Koethe D, Gerth C, Gross S, Schreiber D, Lilley K. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry. 2008;13(12):1118–28.

PubMed  CAS  Google Scholar 

Han S, Xu Y, Gao M, Wang Y, Wang J, Liu Y, Wang M, Zhang X. Serum apolipoprotein E concentration and polymorphism influence serum lipid levels in Chinese Shandong Han population. Medicine (Baltimore). 2016;95(50):e5639.

CAS  Google Scholar 

Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE. 2012;7(6):e34078.

PubMed  PubMed Central  CAS  Google Scholar 

Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155(6):487–95.

PubMed  Google Scholar 

Raygani AV, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer’s disease. Neurosci Lett. 2006;408(1):68–72.

PubMed  CAS  Google Scholar 

Lumsden AL, Mulugeta A, Zhou A, Hyppönen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine. 2020;59:102954.

PubMed  PubMed Central  Google Scholar